33
Views
0
CrossRef citations to date
0
Altmetric
Research Article

The impact of low-dose methotrexate on erectile dysfunction, sex hormone profile and spermiogram in male patients with psoriasis: a prospective study

, , , &
Received 15 Apr 2024, Accepted 23 May 2024, Published online: 03 Jun 2024

References

  • von Csiky-Sessoms S, Lebwohl M. What’s new in psoriasis. Dermatol Clin. 2019;37(2):129–136. doi:10.1016/j.det.2018.11.001.
  • Bakshi H, Nagpal M, Singh M, et al. Treatment of psoriasis: a comprehensive review of entire therapies. Curr Drug Saf. 2020;15(2):82–104.
  • Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the ınternational psoriasis council. J Am Acad Dermatol. 2020;82(1):117–122.
  • Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present and future. Clin Exp Dermatol. 2013;38(6):573–588. doi:10.1111/ced.12062.
  • Shamberger RC, Rosenberg SA, Seipp CA, et al. Effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma. Cancer Treat Rep. 1981;65(9-10):739–746.
  • Malaviya AN, Sharma A, Agarwal D, et al. Low-dose and high-dose methotrexate are two different drugs in practical terms. Int J Rheum Dis. 2010;13(4):288–293.
  • Wylie G, Evans CD, Gupta G. Reduced libido and erectile dysfunction: rarely reported side-effects of methotrexate. Clin Exp Dermatol. 2009;34(7):e234–e234. doi:10.1111/j.1365-2230.2008.03082.x.
  • Theodosiou G, Svensson A. Methotrexate-associated sexual dysfunction: two case reports. Acta Derm Venereol. 2017;97(9):1132–1133. doi:10.2340/00015555-2714.
  • AlEssa RK, AlJasser MI. Methotrexate-associated reduced libido: a case report and review of the literature. Clin Exp Dermatol. 2021;46(7):1350–1352. doi:10.1111/ced.14745.
  • Egeberg A, Hansen PR, Gislason GH, et al. Erectile dysfunction in male adults With atopic dermatitis and psoriasis. J Sex Med. 2017;14(3):380–386. doi:10.1016/j.jsxm.2016.12.233.
  • Bardazzi F, Odorici G, Ferrara F, et al. Sex and the PASI: patients affected by a mild form of psoriasis are more predisposed to have a more severe form of erectile dysfunction. J Eur Acad Dermatol Venereol. 2016;30(8):1342–1348. doi:10.1111/jdv.13625.
  • Tasliyurt T, Bilir Y, Sahin S, et al. Erectile dysfunction in patients with psoriasis: potential impact of the metabolic syndrome. Eur Rev Med Pharmacol Sci. 2014;18(4):581–586.
  • Ji S, Zang Z, Ma H, et al. Erectile dysfunction in patients with plaque psoriasis: the relation of depression and cardiovascular factors. Int J Impot Res. 2016;28(3):96–100. doi:10.1038/ijir.2016.6.
  • Bhat T, Coughlin CC. Mood changes with methotrexate therapy for dermatologic disease. Pediatr Dermatol. 2018;35(2):253–254. doi:10.1111/pde.13406.
  • Maas R, Schwedhelm E, Albsmeier J, et al. The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med. 2002;7(3):213–225. doi:10.1191/1358863x02vm429ra.
  • Salvio G, Ciarloni A, Cutini M, et al. Hyperhomocysteinemia: focus on endothelial damage as a cause of erectile dysfunction. Int J Mol Sci. 2021;22(1):418. doi:10.3390/ijms22010418.
  • Balanescu AR, Bojinca VC, Bojinca M, et al. Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases. Exp Ther Med. 2019;17(2):1024–1029.
  • van Ede AE, Laan RF, Blom HJ, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford)). 2002;41(6):658–665. doi:10.1093/rheumatology/41.6.658.
  • Deyab G, Hokstad I, Whist JE, et al. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis. Arthritis Res Ther. 2017;19(1):232. doi:10.1186/s13075-017-1439-1.
  • Akindele OO, Kunle-Alabi OT, Oghenetega BO, et al. Effects of methotrexate on serum testosterone level in sleep deprived male wistar rats. Afr J Med Med Sci. 2015;44(2):145–150.
  • Pınar N, Çakırca G, Özgür T, et al. The protective effects of alpha lipoic acid on methotrexate induced testis injury in rats. Biomed Pharmacother. 2018;97:1486–1492. doi:10.1016/j.biopha.2017.11.078.
  • Saxena AK, Dhungel S, Bhattacharya S, et al. Effect of chronic low dose of methotrexate on cellular proliferation during spermatogenesis in rats. Arch Androl. 2004;50(1):33–35.
  • Felemban SG, Aldubayan MA, Alhowail AH, et al. Vitamin B17 ameliorates methotrexate-ınduced reproductive toxicity, oxidative stress, and testicular ınjury in male rats. Oxid Med Cell Longev. 2020;2020:4372719–11. doi:10.1155/2020/4372719.
  • Aguirre MA, Vélez A, Romero M, et al. Gynecomastia and sexual impotence associated with methotrexate treatment. J Rheumatol. 2002;29(8):1793–1794.
  • Perez-Garcia LF, Roder E, Krijthe BP, et al. Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX). Ann Rheum Dis. 2023;82(8):1068–1075. doi:10.1136/ard-2023-224032.
  • Günther E. [Andrologic examinations in the antimetabolite therapy of psoriasis]. Dermatol Monatsschr. 1970;156(5):498–502.
  • Grunnet E, Nyfors A, Hansen KB. Studies of human semen in topical corticosteroid-treated and in methotrexate-treated psoriatics. Dermatologica. 1977;154(2):78–84. doi:10.1159/000251036.
  • Pandhi D, Gupta R, Singal A. Gynaecomastia with oligospermia: an unusual complication of low-dose methotrexate for pustular psoriasis. Clin Exp Dermatol. 2006;31(1):138–140. doi:10.1111/j.1365-2230.2005.01925.x.
  • Sussman A, Leonard JM. Psoriasis, methotrexate, and oligospermia. Arch Dermatol. 1980;116(2):215–217. doi:10.1001/archderm.1980.01640260091025.
  • Gutierrez JC, Hwang K. The toxicity of methotrexate in male fertility and paternal teratogenicity. Expert Opin Drug Metab Toxicol. 2017;13(1):51–58. doi:10.1080/17425255.2017.1230198.
  • Krakowsky Y, Grober ED. Testosterone deficiency – establishing a biochemical diagnosis. EJIFCC. 2015;26(2):105–113.
  • Tsujimura A, Matsumiya K, Matsuoka Y, et al. Bioavailable testosterone with age and erectile dysfunction. J Urol. 2003;170(6 Pt 1):2345–2347. doi:10.1097/01.ju.0000089768.17091.c0.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.